Analysts forecast that Neon Therapeutics Inc (NASDAQ:NTGN) will report ($0.65) earnings per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Neon Therapeutics’ earnings. The highest EPS estimate is ($0.42) and the lowest is ($0.76). Neon Therapeutics posted earnings per share of ($0.84) in the same quarter last year, which suggests a positive year-over-year growth rate of 22.6%. The business is expected to issue its next quarterly earnings report on Monday, March 9th.
On average, analysts expect that Neon Therapeutics will report full year earnings of ($2.54) per share for the current financial year, with EPS estimates ranging from ($3.01) to ($1.71). For the next year, analysts expect that the firm will post earnings of ($1.60) per share, with EPS estimates ranging from ($2.86) to ($1.02). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Neon Therapeutics.
Neon Therapeutics (NASDAQ:NTGN) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.04).
In related news, insider Richard Gaynor sold 22,322 shares of Neon Therapeutics stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $1.24, for a total value of $27,679.28. Following the sale, the insider now owns 201,822 shares of the company’s stock, valued at approximately $250,259.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 38.93% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the stock. FNY Investment Advisers LLC acquired a new stake in Neon Therapeutics in the 3rd quarter valued at $361,000. Vanguard Group Inc. grew its stake in Neon Therapeutics by 3.6% in the 2nd quarter. Vanguard Group Inc. now owns 612,398 shares of the company’s stock valued at $2,903,000 after acquiring an additional 21,387 shares during the period. BlackRock Inc. grew its stake in Neon Therapeutics by 11.6% in the 2nd quarter. BlackRock Inc. now owns 765,850 shares of the company’s stock valued at $3,631,000 after acquiring an additional 79,729 shares during the period. Bank of New York Mellon Corp grew its stake in Neon Therapeutics by 112.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 71,443 shares of the company’s stock valued at $339,000 after acquiring an additional 37,755 shares during the period. Finally, Northern Trust Corp grew its stake in Neon Therapeutics by 8.5% in the 2nd quarter. Northern Trust Corp now owns 166,467 shares of the company’s stock valued at $789,000 after acquiring an additional 12,971 shares during the period. 58.19% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ NTGN traded down $0.07 during midday trading on Wednesday, reaching $1.00. 673,569 shares of the stock were exchanged, compared to its average volume of 277,765. The firm has a market cap of $32.31 million, a price-to-earnings ratio of -0.18 and a beta of 1.32. Neon Therapeutics has a twelve month low of $0.98 and a twelve month high of $7.51. The firm has a 50-day simple moving average of $1.76 and a two-hundred day simple moving average of $3.09. The company has a quick ratio of 4.59, a current ratio of 4.59 and a debt-to-equity ratio of 0.15.
Neon Therapeutics Company Profile
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Read More: Why is the LIBOR significant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.